![](/img/cover-not-exists.png)
PCSK9 inhibition augments the therapeutic effect of ezetimibe in lowering intestinal apolipoprotein B lipoprotein production
Rashid, S., Melone, M., Tavori, H., Guinzioni, I., Neff, D., Fazio, S.Volume:
235
Language:
english
Journal:
Atherosclerosis
DOI:
10.1016/j.atherosclerosis.2014.05.774
Date:
August, 2014
File:
PDF, 50 KB
english, 2014